Expansion Therapeutics

    Drug #1: ERX-963

    Approach: Unknown

    Status: In June 2019 Expansion commenced a Phase 1 trial in 12 adult-onset myotonic dystrophy patients.

    

     Drug #2: Small molecule RNA inhibitor

     Status: Preclinical

     Company Website with description of approach

     Video from 2018 MDF Conference

     January 3, 2018 Press Release on Expansion's launch 

     Article on preclinical tests of Expansion's DM1 drug

     Publication of preclinical tests

     September 14, 2019 Presentation at Myotonic Conferenct (1:00)

     Patent Application:  MODULARLY ASSEMBLED SMALL MOLECULES FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1